C. Robert Horsburgh, MDProfessor, Epidemiology
BiographyDr. Horsburgh has 30 years of experience in public health and medicine. He currently holds faculty positions in the Department of Biostatistics and the Department of Medicine. Dr. Horsburgh teaches courses in the Epidemiology of AIDS and the Epidemiology of Tuberculosis. He has focused his research on tuberculosis, nontuberculous mycobacterial infections and opportunistic infections in AIDS and has served as the National Steering Committee Co-Chairman of the Tuberculosis Trials Consortium and the Tuberculosis Epidemiologic Studies Consortium. He is currently the Chairman of the Steering Committee of RESIST-TB, an international organization dedicated to improving MDR-TB treatment through Clinical Trials.
- Professor of Epidemiology, Epidemiology, Boston University School of Public Health
- Professor, Infectious Disease, Medicine, Boston University School of Medicine
- Professor, Biostatistics, Boston University School of Public Health
- Boston Medical Center
- Case Western Reserve University, MD
- Yale University, MUS
- Princeton University, AB
- Published on 3/1/2014
Horsburgh CR. Tuberculosis. Eur Respir Rev. 2014 Mar 1; 23(131):36-9.
- Published on 1/28/2014
Linas BP, Barter DM, Leff JA, Dilorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS. 2014 Jan 28; 28(3):365-76.
- Published on 10/25/2013
Brigden G, Nyang''wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014 Jan 1; 92(1):68-74.
- Published on 10/18/2013
Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol. 2014 Jan 15; 179(2):216-25.
- Published on 3/28/2013
Horsburgh CR, Shea KM, Phillips P, Lavalley M. Randomized clinical trials to identify optimal antibiotic treatment duration. Trials. 2013; 14:88.
- Published on 3/1/2013
O'Donnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh CR. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis. 2013 Mar; 19(3):416-24.
- Published on 1/29/2013
Hochberg NS, Horsburgh CR. Prevention of tuberculosis in older adults in the United States: obstacles and opportunities. Clin Infect Dis. 2013 May; 56(9):1240-7.
- Published on 12/4/2012
Horsburgh CR, Haxaire-Theeuwes M, Lienhardt C, Wingfield C, McNeeley D, Pyne-Mercier L, Keshavjee S, Varaine F. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013 Feb; 17(2):146-52.
- Published on 11/15/2012
Reed C, Bliss C, Stuver SO, Heeren T, Tumilty S, Horsburgh CR, Samet JH, Cotton DJ. Predictors of active injection drug use in a cohort of patients infected with hepatitis C virus. Am J Public Health. 2013 Jan; 103(1):105-11.
- Published on 12/8/2011
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR, Chaisson RE. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011 Dec 8; 365(23):2155-66.
View 58 more publications:View full profile at BUMC